Liver transplantation in transthyretin amyloidosis: Issues and challenges

Liver Transplantation

Volumn 21, Issue 3, 2015, Pages 282-292

  Carvalho, Andreia ^a   Rocha, Ana ^b,c   Lobato, Luísa ^b,c  

^a University of Porto   (Portugal)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN;

AMYLOIDOSIS; BODY MASS; CARDIOMYOPATHY; DISEASE COURSE; DISEASE DURATION; HEART DEATH; HEART TRANSPLANTATION; HEPATIC ARTERY THROMBOSIS; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MALNUTRITION; NUTRITIONAL STATUS; PERIPHERAL NEUROPATHY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEPTICEMIA; SURGICAL MORTALITY; SURVIVAL RATE; TRANSTHYRETIN AMYLOIDOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; AMYLOID NEUROPATHIES, FAMILIAL; GENETIC PREDISPOSITION; GENETICS; LIVER; METABOLISM; MORTALITY; MUTATION; PATIENT SELECTION; PROCEDURES; TIME;

AMYLOID NEUROPATHIES, FAMILIAL; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; LIVER TRANSPLANTATION; MUTATION; PATIENT SELECTION; PREALBUMIN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923535811     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24058     Document Type: Review

References (81)

1. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31.
2. Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013;47:157-162.
3. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36:411-423.
4. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62:1057-1062.
5. Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 2000;6:263-276.
6. Araki S, Ando Y. Transthyretin-related familial amyloidotic polyneuropathy-progress in Kumamoto, Japan (1967-2010). Proc Jpn Acad Ser B Phys Biol Sci 2010;86: 694-706.
7. Andrade C. A peculiar formof peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-427.
8. Adams D, Théaudin M, Cauquil C, Algalarrondo V, Slama M. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep 2014;14:435.
9. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40:242-246.
10. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-1116.
11. Familial Amyloidotic Polyneuropathy World Transplant Registry. Results from the Familial World Transplant Registry. http://www.fapwtr.org/ram-fap.htm. Accessed March 2014.
12. Suhr OB, Ericzon BG, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl 2002;8:787-794.
13. Juneblad K, Näslund A, Olofsson BO, Suhr OB. Outcome of exercise electrocardiography in familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation. Amyloid 2004;11: 208-213.
14. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl 2009;15:1229-1235.
15. Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007;7:2597-2604.
16. Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid 2005;12:233-238.
17. Okamoto S, Zhao Y, Lindqvist P, Backman C, Ericzon BG, Wijayatunga P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid 2011; 18:200-205.
18. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Nakamura T, et al. Impact of aging on the progression of neuropathy after liver transplantation in transthyretin Val30Met amyloidosis. Muscle Nerve 2012;46:964-970.
19. Suhr OB, Holmgren G, Steen L, Wikström L, Norden G, Friman S, et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995;60:933-938.
20. Suhr OB, Ando Y, Holmgren G, Wikström L, Friman S, Herlenius G, Ericzon BG. Liver transplantation in familial amyloidotic polyneuropathy (FAP). A comparative study of transplanted and non-transplanted patient's survival. Transpl Int 1998;11(suppl 1):S160-S163.
21. Jonsén E, Suhr OB, Tashima K, Athlin E. Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life. Amyloid 2001;8:52-57.
22. Bittencourt PL, Couto CA, Farias AQ, Marchiori P, Bosco Massarollo PC, Mies S. Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil. Liver Transpl 2002;8:34-39.
23. Franz C, Hoffmann K, Hinz U, Singer R, Hund E, Gotthardt DN, et al. Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis. Clin Transplant 2013;27(suppl 25):40-48.
24. Suhr O, Danielsson A, Rydh A, Nyhlin N, Hietala SO, Steen L. Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig Dis Sci 1996;41:1909-1914.
25. Parrilla P, Ramirez P, Andreu LF, Bueno SF, Robles R, Miras M, et al. Long-term results of liver transplantation in familial amyloidotic polyneuropathy type I. Transplantation 1997;64:646-649.
26. Ando Y. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol 2005;38:142-154.
27. Suhr OB, Ericzon BG. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 2012;19(suppl 1):78-80.
28. Pomfret EA, Lewis WD, Jenkins RL, Bergethon P, Dubrey SW, Reisinger J, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998;65:918-925.
29. Coutinho MC, Cortez-Dias N, Cantinho G, Conceiçao I, Oliveira A, Bordalo e Sá A, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging 2013;6:627-636.
30. Okamoto S, Wixner J, Ericzon BG, Friman S, Lindqvist P, Henein M, Suhr OB. Prognostic value of pretransplant cardiomyopathy in Swedish liver transplanted patients for familial amyloidotic polyneuropathy. Amyloid 2011;18(suppl 1):171-173.
31. Wilczek HE, Larsson M, Ericzon BG; for FAPWTR. Longterm data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011; 18(suppl 1):193-195.
32. García-Herola A, Prieto M, Pascual S, Berenguer M, López-Viedma B, Mir J, et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg 1999;5:246-248.
33. Suhr OB. Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications. Amyloid 2003;10(suppl 1):77-83.
34. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012;93:1017-1023.
35. Sandgren O, Kjellgren D, Suhr OB. Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy. Acta Ophthalmol 2008;86:520-524.
36. Hara R, Kawaji T, Ando E, Ohya Y, Ando Y, Tanihara H. Impact of liver transplantation on transthyretin-related ocular amyloidosis in Japanese patients. Arch Ophthalmol 2010;128:206-210.
37. Monteiro E, Perdigoto R, Furtado AL. Liver transplantation for familial amyloid polyneuropathy. Hepatogastroenterology 1998;45:1375-1380.
38. Acosta F, De La Morena G, Villegas M, Sansano T, Reche M, Beltran R, et al. Cardiac evaluation of patients with familial amyloidotic polyneuropathy proposed for liver transplantation. Transplant Proc 1999;31:2372.
39. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-1300.
40. Okamoto S, Hörnsten R, Obayashi K, Wijayatunga P, Suhr OB. Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant). Liver Transpl 2011;17:122-128.
41. Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schäfers HJ, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010;16:314-323.
42. Acosta F, Sansano T, Rodriguez MA, Contreras RF, Reche M, Beltran R, et al. Need for venovenous bypass in patients with familial amyloidotic polyneuropathy treated with liver transplantation. Transplant Proc 1999;31: 2394-2395.
43. Parrilla P, Ramirez P, Bueno FS, Robles R, Acosta F, Miras M, et al. Clinical improvement after liver transplantation for type I familial amyloid polyneuropathy. Br J Surg 1995;82:825-828.
44. Vieira de Melo PS, Miranda LE, Batista LL, Neto OC, Amorim AG, Sabat BD, et al. Orthotopic liver transplantation without venovenous bypass using the conventional and piggyback techniques. Transplant Proc 2011;43: 1327-1333.
45. Escobar B, Taura P, Barreneche N, Beltran J, Balust J, Martinez-Palli G, et al. The influence of the explant technique on the hemodynamic profile during sequential domino liver transplantation in familial amyloid polyneuropathy patients. Liver Transpl 2009;15:869-875.
46. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012;78:637-643.
47. Nyhlin N, Anan I, El SM, Ando Y, Suhr OB. Reduction of free radical activity in amyloid deposits following liver transplantation for familial amyloidotic polyneuropathy. J Intern Med 2002;251:136-141.
48. Shimojima Y, Morita H, Kobayashi S, Takei Y, Ikeda S. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol 2008;255:1220-1225.
49. Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr OB, Obayashi K, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 1999; 171:19-23.
50. Okamoto S, Yamashita T, Ando Y, Ueda M, Misumi Y, Obayashi K, et al. Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation. Intern Med 2008;47:2133-2137.
51. Ohya Y, Okamoto S, Tasaki M, Ueda M, Jono H, Obayashi K, et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today 2011;41:1211-1218.
52. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007;7:235-242.
53. Rocha A, Lobato L, Silva H, Beirao I, Santos J, Pessegueiro H, et al. Characterization of end-stage renal disease after liver transplantation in transthyretin amyloidosis (ATTR V30M). Transplant Proc 2011;43:189-193.
54. Rela M, Muiesan P, Heaton ND, Corbally M, Hajj H, Mowat AP, et al. Orthotopic liver transplantation for hepatic-based metabolic disorders. Transpl Int 1995;8: 41-44.
55. Bispo M, Marcelino P, Freire A, Martins A, Mourao L, Barroso E. High incidence of thrombotic complications early after liver transplantation for familial amyloidotic polyneuropathy. Transpl Int 2009;22:165-171.
56. Lisman T, Porte RJ. Hepatic artery thrombosis after liver transplantation: more than just a surgical complication? Transpl Int 2009;22:162-164.
57. Nunes RJ, de Oliveira P, Lages A, Becker JD, Marcelino P, Barroso E, et al. Transthyretin proteins regulate angiogenesis by conferring different molecular identities to endothelial cells. J Biol Chem 2013;288:31752-31760.
58. Telles-Correia D, Cortez-Pinto H, Barbosa A, Mega I, Monteiro E. Quality of life following liver transplantation: a comparative study between familial amyloid neuropathy and liver disease patients. BMC Gastroenterol 2009;9:54.
59. Shaz BH, Gordon F, Lewis WD, Jenkins RL, Skinner M, Khettry U. Orthotopic liver transplantation for familial amyloidotic polyneuropathy: a pathological study. Hum Pathol 2000;31:40-44.
60. Furtado A, Tomé L, Oliveira FJ, Furtado E, Viana J, Perdigoto R. Sequential liver transplantation. Transplant Proc 1997;29:467-468.
61. Furtado AJ. Domino liver transplantation using FAP grafts. HUC experience-hopes and realities. Amyloid 2003;10(suppl 1):84-87.
62. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005;352:2356.
63. Sousa MM, Ferrao J, Fernandes R, Guimaraes A, Geraldes JB, Perdigoto R, et al. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest 2004;84:865-873.
64. Yamamoto S, Wilczek HE, Iwata T, Larsson M, Gjertsen H, Söderdahl G, et al. Long-term consequences of domino liver transplantation using familial amyloidotic polyneuropathy grafts. Transpl Int 2007;20:926-933.
65. Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006;6:2512-2515.
66. Barreiros AP, Geber C, Birklein F, Galle PR, Otto G. Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. Liver Transpl 2010;16:109.
67. Lladó L, Baliellas C, Casasnovas C, Ferrer I, Fabregat J, Ramos E, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010;16:1386-1392.
68. Samuel D, Adams D. Domino liver transplantation from familial amyloidotic polyneuropathy donors: how close is the Damocles sword to the recipient? Transpl Int 2007; 20:921-923.
69. Bolte FJ, Schmidt HH, Becker T, Braun F, Pascher A, Klempnauer J, et al. Evaluation of domino liver transplantations in Germany. Transpl Int 2013;26:715-723.
70. Obayashi K, Yamashita T, Tasaki M, Ueda M, Shono M, Jono H, et al. Amyloid neuropathy in a younger domino liver transplanted recipient. Muscle Nerve 2011;43:449-450.
71. Ericzon BG. Domino transplantation using livers from patients with familial amyloidotic polyneuropathy: should we halt? Liver Transpl 2007;13:185-187.
72. Antonini TM, Lozeron P, Lacroix C, Mincheva Z, Durrbach A, Slama M, et al. Reversibility of acquired amyloid polyneuropathy after liver retransplantation. Am J Transplant 2013;13:2734-2738.
73. Kitchens WH. Domino liver transplantation: indications, techniques, and outcomes. Transplant Rev (Orlando) 2011;25:167-177.
74. Pilato E, Dell'Amore A, Botta L, Arpesella G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur J Cardiothorac Surg 2007;32:180-182.
75. Arpesella G, Chiappini B, Marinelli G, Mikus PM, Dozza F, Pierangeli A, et al. Combined heart and liver transplantation for familial amyloidotic polyneuropathy. J Thorac Cardiovasc Surg 2003;125:1165-1166.
76. Lobato L, Beirao I, Seca R, Pessegueiro H, Rocha MJ, Queiroz J, et al. Combined liver-kidney transplantation in familial amyloidotic polyneuropathy TTR V30M: nephrological assessment. Amyloid 2011;18(suppl 1):190-192.
77. Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012;7:1337-1346.
78. González MR, Ramírez P, Cascales P, Domingo J, López MD, Rios A, et al. Thirteen cases of liver-kidney transplantation. Transplant Proc 2010;42:3162-3163.
79. Hund E. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis. Appl Clin Genet 2012;5:37-41.
80. Isono K, Jono H, Ohya Y, Shiraki N, Yamazoe T, Sugasaki A, et al. Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells. Stem Cell Res 2014;12:574-583.
81. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 2012;18:315-319.